Statements (12)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Garrett Winslow
|
| gptkbp:focusesOn |
development of therapies for rare and orphan diseases
|
| gptkbp:foundedYear |
2011
|
| gptkbp:headquartersLocation |
gptkb:Rockville,_Maryland,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:renamed |
Avalo Therapeutics
|
| gptkbp:tradedOn |
NASDAQ:CERC
|
| gptkbp:website |
https://www.avalotx.com/
|
| gptkbp:bfsParent |
gptkb:Peter_Greenleaf
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cerecor
|